SCHEMBL7935620

SCHEMBL7935620

Nc1ncccc1NCc1cc(NC(=O)c2ccc(O)cn2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 7/20 0.53
PRKCI P41743 4/20 0.44
GRM4 Q14833 3/20 0.39
SHMT2 P34897 1/20 0.38
HDAC3 O15379 3/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC8 Q9BY41 3/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
NCOR1 O75376 1/20 0.37
JAK2 O60674 1/20 0.37
TYK2 P29597 1/20 0.37
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7941379 0.90 BACE1 (0.53) BACE1PRKCIGRM4
SCHEMBL7932754 0.89 BACE1 (0.55) BACE1PRKCIGRM4HDAC3HDAC1
SCHEMBL7939305 0.89 BACE1 (0.52) BACE1PRKCIGRM4HDAC3HDAC1
SCHEMBL7941381 0.89 BACE1 (0.52) BACE1PRKCI
SCHEMBL7943507 0.87 BACE1 (0.57) BACE1PRKCIGRM4SHMT2HDAC3
SCHEMBL7935614 0.86 BACE1 (0.50) BACE1PRKCIHDAC3
SCHEMBL7944708 0.86 BACE1 (0.52) BACE1PRKCIGRM4SHMT2
SCHEMBL7941890 0.86 BACE1 (0.59) BACE1PRKCIGRM4
SCHEMBL7945304 0.86 BACE1 (0.50) BACE1GRM4
SCHEMBL7942253 0.86 BACE1 (0.58) BACE1PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885PRKCI 2747/4885GRM4 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.